Drug Name:
PARNATE Rx

Generic Name and Formulations:
Tranylcypromine (as sulfate) 10mg; tabs.
Company:
Concordia Pharmaceuticals Inc.
Therapeutic Use:
Indications for PARNATE:
Major depressive disorder in adults who have not responded adequately to other antidepressants (not for initial treatment).
Adult:
30mg daily in divided doses. If inadequate response, may increase in 10mg/day increments every 1–3 weeks; usual max 60mg/day. Switching to/from other antidepressants: see full labeling.
Children:
Not established.
Contraindications:
See Interactions. Pheochromocytoma. Catecholamine-releasing paragangliomas. To avoid potentially severe or fatal interactions, allow sufficient drug-free interval (at least 1 week or 4–5 half lives; see full labeling) between tranylcypromine and non-selective H1 receptor antagonists, other MAOIs (eg, linezolid, IV methylene blue), SSRIs (eg, fluoxetine), SNRIs, tricyclic antidepressants, amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine, amphetamines, methylphenidates and derivatives, sympathomimetics, triptans, buspirone, carbamazepine, cyclobenzaprine, dextromethorphan, dopamine, hydroxytryptophan, levodopa, methyldopa, meperidine, milnacipran, rasagiline, reserpine, s-adenosyl-L-methionine (SAM-e), tapentadol, tetrabenazine, tryptophan, mirtazapine.
Boxed Warning:
Suicidal thoughts and behaviors. Hypertensive crisis with significant tyramine use.
Warnings/Precautions:
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults; monitor for clinical worsening or unusual changes in all patients. Hypertensive crisis with significant tyramine use; monitor and discontinue if occurs. Hyperthyroidism. Hypertension. Cardiovascular or cerebrovascular disorders. History of headaches. Assess BP prior to initiation and monitor closely during treatment. Screen for bipolar disorder, mania, or hypomania. Depression. Monitor for hepatotoxicity; discontinue if occurs. Possible increased risk of CNS effects in those with cirrhosis. Diabetes (monitor glucose). Discontinue at least 10 days before elective surgery. Avoid abrupt cessation. Elderly. Labor & delivery. Pregnancy. Nursing mothers: not recommended.
Pharmacological Class:
MAOI.
Interactions:
See Contraindications. Do not start within 5 weeks of fluoxetine. Avoid high-tyramine foods and beverages (eg, aged cheese, aged/fermented meats, salami, pickled herring, chocolate, beer, yeast extract, sauerkraut, soybean products, broad beans) during and for 2 weeks after discontinuation. Risk of serotonin syndrome with serotonergic drugs (eg, SSRIs, SNRIs, TCAs, triptans, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's wort, SAM-e, other MAOIs); discontinue if occurs. Caution with hypotensive drugs, β-blockers, CNS depressants (eg, opioids, alcohol, sedatives, hypnotics), altretamine, chlorpromazine, droperidol, entacapone, tolcapone, methadone, metoclopramide, oxcarbazepine. Increased hypoglycemia with concomitant insulin, antidiabetic agents; may need lower dose of these.
Adverse Reactions:
Dry mouth, dizziness, insomnia, sedation, headache, overexcitement, constipation, blurred vision, tremor; hypertensive crises, hypertension, postural hypotension, syncope, hepatitis, elevated liver enzymes, seizures (monitor).
How Supplied:
Tabs—100
Sign Up for Free e-newsletters
ONA Articles
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Nurse-Led vs Oncologist-Led Breast Cancer Follow-up Program: Early Feasibility Results of an Ongoing Study
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Substitute for Lidocaine
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Identifying the Needs of Multidisciplinary Team Treating Geriatics Cancer Patients
- Hypofractionated Radiotherapy for Prostate Cancer: The New ASTRO/ASCO/AUA Guideline
- Risk of Hospitalization Remains High for Survivors of Childhood Leukemia
- Sequence of Immunotherapy, Targeted Therapy, Radiation Therapy Influences Overall Survival in Melanoma Brain Metastases
- Survey Demonstrates Implicit Bias Toward Cervical Cancer Diagnoses Among Nurses, Women
- Use of Watchful Waiting Up for Low-Risk Localized Prostate Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Genitourinary Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Rare Cancers | Regimens | |
Skin Cancer | Regimens | Drugs |